Systematic review of methydopa and labetalol in the treatment of hypertension disorders in pregnancy
10.13699/j.cnki.1001-6821.2017.17.028
- VernacularTitle:甲基多巴和拉贝洛尔治疗妊娠期高血压疾病的系统评价
- Author:
Rui-Ting WEN
1
;
Lin HUANG
;
Zhi-Ying YU
;
Wan-Yu FENG
Author Information
1. 北京大学人民医院药剂科,北京100044
- Keywords:
methyldopa;
labetalol;
hypertension;
pregnancy;
Meta-analysis
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(17):1710-1712
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of methyldopa and labetalol in treating hypertension disorders in pregnancy.Methods Databases of MedLine,Cochrane Library,EMbase,CNKI,Wanfang,and VIP were searched for published randomized controlled trials (RCTs) on hypertension disorders in pregnancy with methyldopa as treatment group and labetalol as control group.Meta-analysis was conducted by RevMan 5.3 software.Results A total of 10 RCTs involving 1285 patients were included.Rates of severe hypertension in treatment group and control group were 6.62％ and 12.21％,respectively.Rates of proteinuria were 15.57％ and 8.52％,rates of adverse drug reaction were 21.82％ and 25.63％,rates of fetal/infant death were 4.19％ and 2.84％.The results of Meta-analysis revealed that there were no significant differences in the above parameters between treatment and control groups.However,plasma viscosity was significantly lower in treatment group compared with that in control group (RR =0.77,95％ CI =0.64-0.90,P ＜ 0.001).Conclusion Methyldopa and labetalol are equally effective and safe in treating hypertension disorders in pregnancy,while methyldopa is more effective in reducing plasma viscosity.
